U.S. Markets close in 4 hrs 33 mins

Celgene Corporation (CELG)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
117.09-0.66 (-0.56%)
As of 11:27AM EDT. Market open.
People also watch
GILDBIIBREGNAMGNALXN
  • this stock deserves a price of 155 or higher. The stock was higher than Apple and Facebook. Soon the big money investors will step in to take advantage of this buy cheap opportunity.
  • why down with good news
  • Amgen news is hurting the whole sector. Too many ETF's and index funds with the same companies in the mix. Any company specific good news gets over-looked!
  • Shorts have jumped onboard many of these biotechs for various reasons (ACA delays, problems with MS drugs, Osteo, etc.) IMO these shorts will cover ahead of ASCO or will be fried! JMO. Pivot 177.55 today BTW!
  • so you sold all that giant tech companies (faang) to load celg and amgn, you prayed over the weekend and thought this time is your turn. When you read the sugar coated news about, you thought great. Only to see red, and more red. Then, you thought it is amgn that dragged celg, so you loaded more celg. A very similar news about celg, and it was too late to sell...
  • NVIV all time low, the next Celgene, science is excellent and they will get FDA approval soon!
    Check it out! best buying opportunity out there!
  • CELG Makes Notable Cross Below Critical 200 Day Moving Average.
  • See why biotech/pharma shareholders are adding this breakthrough wound care to their portfolio. BioLargo recent 10Q states:
    • Advanced Wound Care products are ready, all studies successfully completed, and they expect to file a 510K with FDA in less than 90 days
    • Woundcare market is over $6 Billion with high growth rate
    • Tanya Rhodes, ex VP of Smith & Nephew Wound Care Product Development is leading the BLGO/Clyra Medical 510K filing
    • BLGO/Clyra Medical Wound Care Products promote healing substantially better than competing products, fight infection better than competing products, are effective against resistant microbials, and are low cost
    • Sales could commence late 2017
    • Sales and or licensing agreement/s could be very significant and fast
    • Company is now commercializing several other disruptive products in large markets

    http://www.clyramedical.com

    https://www.sec.gov/Archives/edgar/data/880242/000143774917009469/blgo20170331_10q.htm

    Clyra Medical | Make Life Better
    www.clyramedical.com
  • This is starting to look bleak
  • good news today didn't overcome bad news from amgen
  • What's going on with this stock? It should be trading for much higher than this.
  • Looks like another GILD in the making.
  • Weak hands are being shaken out.. Biotech is weak in general today. This has absolutely nothing to do with the recent Argus call, which was written by an imbecile (if anything, his call should be interpreted as a contrarian tell).
    Nothing has fundamentally changed.
  • FANTASTIC NEWS OUT ...RALLYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY
    (AXSM) Market Cap $85 M/Cash $60 M / 5x BIG Phase 3 programs in various indications targeting large Markets with first results in Q3 2017 =20 BAGGER ..FANTASTIC OPPORTUNITY !

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $85 million and $60 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $85 Million
    Cash: $60.6 Million(cash runway into the first quarter of 2019.)
    Price:$3.70

    Shares Out: 23 Million

    Anticipated Near-Term Clinical Milestones

    Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)

    Clinical Trial Readouts:

    -- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)

    -- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)

    -- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)

    New Presentation April
    http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NjY0Mzk1fENoaWxkSUQ9MzcyMTk4fFR5cGU9MQ==&t=1

    HUGE Pipeline targeting Billion Dollar Markets:
    http://axsome.com/wp-content/uploads/2016/11/Axsome_Dec2016_Pipeline.png

    AXS-05 Treatment Resistant Depression in Phase 3 -(Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.)

    AXS-05 Agitation in Alzheimer’s Disease in Phase 2/3 -(No approved medication = unmet medical need. 2M patients in the U.S.)

    AXS-02 Complex Regional Pain Syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status) -(No approved drug = high unmet need. 80,000 new cases per year in the U.S.)

    AXS-02 Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs) in Phase 3 (SPA & Fast Track) -(7M patients in the U.S.)

    AXS-02 Chronic Low Back Pain(CLBP) with Modic Changes (MCs) in Phase 3 -(1.6M patients in the U.S.)

  • Any word on what when down when Celgene's ceo and others met with Trump last Monday? I haven't seen anything about it from the press! Just curious as all my biotechs have been in a bloodbath and was thinking it went badly maybe!
  • all time high is 137 sooner rather than latter we brk that mark
  • CELG is one of the companies meeting with Trump Monday

    Vice President Mike Pence, President Donald Trump’s daughter Ivanka Trump and his son-in-law Jared Kushner will attend the May 8 summit, along with the head of the U.S. National Institutes of Health, executives from Celgene Corp. and Regeneron Pharmaceuticals Inc., and leaders of top research universities and hospitals.

    The meeting is described in the memo as a chance for “private sector and thought leaders to describe their institution and its connection to federal funding.” The Trump administration has proposed cutting $1.23 billion from the NIH’s budget this fiscal year, and $5.8 billion next year, an about 18 percent reduction. Most of the proposed 2017 cuts would have come from research grants.
  • weak
  • ten bagger..Guess you're speaking about your wife?
  • The trading setup for CELG looks very alluring with rsi hitting 42.95. The last time things got this interesting there were explosions. if you guys have questions you should ask awesome-STOCKS. They often respond to my emails which is helpful.